Current Editions
Serendipity drives discovery in psychiatry, engineering gets it across the line, says Steve Paul
From muscarinic breakthroughs to next-gen psychedelics, what’s changing — and what isn’t — in the search for psychiatry medicines: The BioCentury Show
Product Development
Emerging Company Profile
Latent Labs: AI-designed, ready-to-develop biologics
Former DeepMind team building frontier models to design drug-like biologics for challenging targets in one step
Finance
Angitia’s latest megaround to fuel mid-stage milestones: Venture Report
Plus: Third Arc augments series A, Syncona’s Slingshot accelerator houses newly launched ALTx, and more
BioCentury ISSN 1097-7201